524731 — Jenburkt Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- IN₹3.83bn
- IN₹3.03bn
- IN₹1.42bn
- 86
- 38
- 68
- 75
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.68 | ||
| Price to Tang. Book | 2.68 | ||
| Price to Free Cashflow | 69.61 | ||
| Price to Sales | 2.73 | ||
| EV to EBITDA | 9.29 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.7% | ||
| Return on Equity | 19.43% | ||
| Operating Margin | 21.68% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 1,188.91 | 1,092.94 | 1,239.8 | 1,367.49 | 1,419.66 | n/a | n/a | 2.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -24.99 | +10.98 | +34.28 | +15.47 | +5.58 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Jenburkt Pharmaceuticals Limited is an India-based company that is engaged in the business of manufacturing, producing, developing and marketing a range of branded pharmaceuticals and health care products. The Company offers pharmaceutical products for various therapeutic areas, analgesic and antipyretics anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer division, cough and cold, muscle relaxants neuropathic pain, nutraceuticals and pain management. The Company's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets and others. The Company's manufacturing plant is located in Sihor-Gujarat. The Company's products are exported to approximately 13 countries globally.
Directors
- Ashish Bhuta CHM
- Ashish Shah CCO
- Dilip Bhuta EDR
- Bharat Bhate NID (63)
- Arun Raskapurwala NID
- Rameshchandra Vora NID
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- June 10th, 1985
- Public Since
- October 18th, 1994
- No. of Employees
- 724
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 4,413,300
- Address
- Nirmala Apartments, MUMBAI, 400058
- Web
- https://jenburkt.com/
- Phone
- +91 2267603603
- Contact
- Vijayan Pillai
- Auditors
- D.R. Mehta & Associates
Upcoming Events for 524731
Jenburkt Pharmaceuticals Ltd Annual Shareholders Meeting
Q1 2025 Jenburkt Pharmaceuticals Ltd Earnings Release
Q2 2025 Jenburkt Pharmaceuticals Ltd Earnings Release
Similar to 524731
Achyut Healthcare
Bombay Stock Exchange
Adline Chem Lab
Bombay Stock Exchange
MPS Pharmaa
Bombay Stock Exchange
Albert David
Bombay Stock Exchange
Ambalal Sarabhai Enterprises
Bombay Stock Exchange
FAQ
What is the Jenburkt Pharmaceuticals share price?
As of Today at 15:29 UTC, shares in Jenburkt Pharmaceuticals are trading at IN₹878.55. This share price information is delayed by 15 minutes.
How has the Jenburkt Pharmaceuticals share price performed this year?
Shares in Jenburkt Pharmaceuticals last closed at IN₹878.55 and the price had moved by +22.47% over the past 365 days. In terms of relative price strength the Jenburkt Pharmaceuticals share price has underperformed the S&P BSE 100 Index by -6.42% over the past year.
What are the analyst and broker recommendations for Jenburkt Pharmaceuticals?
There is no consensus recommendation for this security.
What is the Jenburkt Pharmaceuticals dividend yield?
The Jenburkt Pharmaceuticals dividend yield is 1.74% based on the trailing twelve month period.
Does Jenburkt Pharmaceuticals pay a dividend?
Last year, Jenburkt Pharmaceuticals paid a total dividend of IN₹15.30, and it currently has a trailing dividend yield of 1.74%.Looking ahead, shares in Jenburkt Pharmaceuticals are due to go ex-dividend on 2024-07-23 and the next dividend pay date is 2024-08-29.
When does Jenburkt Pharmaceuticals next pay dividends?
Jenburkt Pharmaceuticals are due to go ex-dividend on 2024-07-23 and the next dividend pay date is 2024-08-29. The historic dividend yield on Jenburkt Pharmaceuticals shares is currently 1.74%.
How do I buy Jenburkt Pharmaceuticals shares?
To buy shares in Jenburkt Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Jenburkt Pharmaceuticals?
As of the previous close price of IN₹878.55, shares in Jenburkt Pharmaceuticals had a market capitalisation of IN₹3.88bn.
Where are Jenburkt Pharmaceuticals shares listed?
Here are the trading details for Jenburkt Pharmaceuticals:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 524731
What kind of share is Jenburkt Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Jenburkt Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Jenburkt Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Jenburkt Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jenburkt Pharmaceuticals. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +15.43%.
As of the last closing price of IN₹878.55, shares in Jenburkt Pharmaceuticals were trading +18.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Jenburkt Pharmaceuticals PE Ratio?
The Jenburkt Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹878.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Jenburkt Pharmaceuticals?
Jenburkt Pharmaceuticals' management team is headed by:
- Ashish Bhuta - CHM
- Ashish Shah - CCO
- Dilip Bhuta - EDR
- Bharat Bhate - NID
- Arun Raskapurwala - NID
- Rameshchandra Vora - NID